AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01383785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracoronary distal injection by aspiration catheter device
Description: Abciximab bolus dosage: 0,125 mg/kg.~Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter.
Study NCT02954783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed.~After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
Study NCT02954783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Observational Control
Description: The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
Study NCT01446640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow derived mesenchymal stem cells
Description: Intravenous administration of up to 1x10\^6 MSCs per kg; intrathecal administration of up to 1x10\^6 MSCs per kg.
Study NCT01204502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSVTK retrovirally-transduced donor T lymphocytes
Description: HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~* dose 1 5x104 cells/kg~* dose 2 5x105 cells/kg
Study NCT02214914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 drinking solution
Study NCT02214914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 tablet
Study NCT02214914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00238914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50mg of oral naltrexone daily
Study NCT00238914 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Naltrexone Therapy (BNT)
Description: a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
Study NCT04202822 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral soft tissues biopsies
Description: Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) will be harvested by the examiner at the time of the surgery (immediately before to start the surgical procedure -T0) and 24 hours after surgery (T24) at the level of the vertical released incisions (VRIs) with a biopsy punch with plunger of 2.0 mm diameter.
Study NCT05511636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU we will be comparing HFNC to standard oxygen therapy. The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
Study NCT03366935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPL and CEI
Description: Procedure: Standard epidural placement(EPL)~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA).
Study NCT03366935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DPE and CEI
Description: Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA).
Study NCT03366935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DPE and PIEB
Description: Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
Study NCT04318509 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GMPOWER
Description: (casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
Study NCT04803656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of COPD patients
Description: Assessments explained in the arm section were made as described in one session.
Study NCT03114709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindful Movement
Description: The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.
Study NCT03114709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10 Keys to Health & Wellbeing
Description: This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
Study NCT01906489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study NCT01906489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study NCT02400281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib besylate
Study NCT00238914 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Compliance Enhancement (CE)
Description: a controlled therapy intended to simulate outpatient psychiatric care.
Study NCT01410812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Receive weekly emails asking participants about their exercise and receive cash.
Study NCT02239614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-LAV
Description: 0.5 mL of the post-transfection LAV F17 vaccine
Study NCT01410812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suggested Tying Intervention
Description: Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym
Study NCT01410812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forced Tying Intervention
Description: Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
Study NCT02733653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream Atherectomy System
Description: A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
Study NCT03111953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass Surgery
Description: In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the Roux limb and the biliopancreatic limb approximately \~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum.
Study NCT03111953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biliopancreatic Diversion Surgery
Description: In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, \~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, \~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
Study NCT01443507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endurance exercise of different duration and intensity
Description: Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
Study NCT00759525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycyrrhetic Acid
Description: 130 mg daily for fourteen days
Study NCT00759525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for fourteen days
Study NCT02738424 — intervention group
Intervention type: OTHER
Intervention: Calculate the ADC scores
Description: The MRI will be performed on the two groups of patients in the usual care. The intervention will be based on the ADC scores calculation. The scores will be obtained with three types of post-processing softwares : Siemens, PACS Carestream, Osirix.
Study NCT01174394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCEAS (Hwato®/ Dongbang®)
Description: Upon insertion of acupuncture needles, dense cranial electro-acupuncture stimulation (DCEAS), is directly delivered on a density of cranial acupoints (in general 6-8 pairs) located on the frontal, parietal, and temporal scalp areas.
Study NCT01174394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Body electro-acupuncture (Hwato®/ Dongbang®)
Description: Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
Study NCT01174394 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Body electro-acupuncture (Hwato®/ Dongbang®)
Description: Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
Study NCT01842997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
Description: 122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
Study NCT02720848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stiffening wire
Description: The stiffening wire will be inserted into the double/single balloon enteroscope.
Study NCT02720848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique
Description: The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
Study NCT04273191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexanolone
Description: Brexanolone will be initiated and administered per the USPI and the associated REMS.
Study NCT01181570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
Study NCT01181570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
Study NCT03632018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART-PLAY
Description: Participants assigned to the HEART-PLAY intervention will receive standard CR. Additionally, they will receive pedometers, group education, and educational materials introduced by peer Health Coaches for 12 months. Before or after their regularly scheduled CR appointments, they will meet at the clinic as a group twice per week to receive Health Tips and participate in discussions. At 8 weeks in to the 12-week CR, they will begin to discuss with their peer Health Coaches the transition from the formal CR setting into community-based exercise. As part of this transition, peer Health Coaches will slowly introduce group community walks and train participants in the proper use of resistance bands. Health Coaches will have talk with their assigned participants about relapse prevention and sustaining exercise following the termination of formal CR.
Study NCT03632018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardiac Rehabilitation
Description: During the 12-week intervention period, the STANDARD intervention participants will receive standard of care by attending the 36 sessions of standard CR as prescribed by his/her physician and administered by the Step Clinic.
Study NCT00803439 — intervention group
Intervention type: DRUG
Intervention: Clobetasol Propionate 0.05% Foam-Reference Product
Description: Small amount applied and evaluated over the course of two days
Study NCT00803439 — intervention group
Intervention type: DRUG
Intervention: Clobetasol Propionate 0.05% Foam-Test product
Description: Small amount applied and evaluated over the course of two days
Study NCT03020771 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: KIRIM-KONGO-VAX
Description: Crimean-Congo Hemorrhagic Fever Vaccine
Study NCT01174394 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: n-CEA (Strietberger®)
Description: Streitberger's non-invasive acupuncture needles were applied to serve as sham control at the same cranial acupoints and the same stimulation modality, except that the needles only adhere to the skin instead of insertion
Study NCT01174394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
Study NCT01174394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
Study NCT01146288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide first, then Acetazolamide
Description: Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
Study NCT01146288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide first, then Furosemide
Description: Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
Study NCT03198806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill aerobic exercise in supine position
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
Study NCT03198806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercise and water intake in supine position
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
Study NCT03198806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill aerobic exercise in orthostatic position
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 10 minutes of recovery at the orthostatic position.
Study NCT03198806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercise and water intake in orthostatic position
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 10 minutes of recovery at the orthostatic position.
Study NCT02098811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1064nm Laser
Description: Patient will be treated with 1064nm Laser prior to abdominoplasty
Study NCT02098811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 940nm Laser
Description: Patient will be treated with 940nm Laser prior to abdominoplasty
Study NCT01270152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
Study NCT02047097 — intervention group
Intervention type: DRUG
Intervention: dimethyl fumarate
Description: Provided under routine clinical care
Study NCT00757692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
Study NCT05218018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Lipid drink
Description: 100 mls of heavy cream
Study NCT00757692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Bicalutamide at 50 mg will be administered orally, daily and continuously.
Study NCT03144869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity monitor and feedback
Description: Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
Study NCT03120377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platform
Description: Whole body vibration training will consist of 12 consecutive weeks with two sessions per week on alternate days. Initially, before training with the vibratory platform, stretches lasting 5 to 10 minutes will be performed, with a series of 60 seconds for each of the following muscle groups: pectorals, sternocleidomastoids, scalenes, quadriceps and ischiatibial muscles. Patients will be monitored through vital signs for follow-up.